Suppr超能文献

微波消融治疗肝脏恶性肿瘤:技术及设备差异的系统评价

Microwave ablation for hepatic malignancies: a systematic review of the technology and differences in devices.

作者信息

Barrow Brooke, Martin Ii Robert C G

机构信息

Department of Surgery, Division of Surgical Oncology, University of Louisville School of Medicine, 315 E. Broadway, Louisville, KY, 40292, USA.

出版信息

Surg Endosc. 2023 Feb;37(2):817-834. doi: 10.1007/s00464-022-09567-2. Epub 2022 Sep 8.

Abstract

BACKGROUND

Microwave ablation (MWA) has become the standard thermal-based treatment for hepatic malignancies in patients who have unresectable disease based on the biology of the tumor, the patients' comorbidities, and certain disease sites. The technical effectiveness, ablation success, local recurrence rates of hepatic malignancies treated with the various commercial microwave ablation devices has not been previously published in the peer reviewed literature. The aim of this systematic review is to summarize the clinical outcomes for the various MWA devices in the use of a hepatic malignancies to best educate hepatic surgeons as well as interventional radiologists.

METHODS

A comprehensive review of the literature and instructions for use of each device that was published from 1/2013 to 12/2020 was performed. The main outcomes extracted were technical success, ablation success, major complications, local and new recurrence rates, recurrence-free survival, ablation volumes, time, and the number of antennas required. A qualitative review of the literature was performed.

RESULTS

In total, 29 studies reporting data on 3250 patients and 4500 tumors were included in this review. Median patient age was 60.5 years (range 3-91). 76.3% (2420 M/753 F) of patients were male. Hepatocellular carcinoma (55%) was the most common tumor pathology followed by colorectal liver metastasis (10%) and cholangiocarcinoma (4%). A majority of studies reported technical success (range, 91.6-100%) and ablation success (range, 73.1-100%), as well as major complications (range, 0-9.1%). Local recurrence (range, 0-50%) was reported by 21 of the studies; however, new recurrence (range, 12.2-64%) was reported less frequently (6 studies) and were further specified in 12, six, and four studies as intrahepatic distant recurrence (11.3-54.2%), extrahepatic distant recurrence (3.6-20%), and metastasis (1.1-36%). A total of three, six, and five studies report disease, progression, and recurrence-free survival rates, respectively.

CONCLUSION

Microwave ablation is frequently used for the treatment of hepatic malignancies. A thorough understanding of the clinical outcomes associated with different pathologies and MWA devices can improve surgeon awareness and help prepare for operative planning and patient management. More consistent reporting of key outcomes in the literature is needed to achieve such an understanding.

摘要

背景

基于肿瘤生物学特性、患者合并症及特定疾病部位,微波消融(MWA)已成为无法切除的肝恶性肿瘤患者的标准热消融治疗方法。此前,各种商用微波消融设备治疗肝恶性肿瘤的技术有效性、消融成功率及局部复发率尚未在同行评审文献中发表。本系统评价的目的是总结各种MWA设备在肝恶性肿瘤治疗中的临床结果,以便更好地指导肝脏外科医生和介入放射科医生。

方法

对2013年1月至2020年12月发表的文献及各设备的使用说明书进行全面综述。提取的主要结果包括技术成功率、消融成功率、主要并发症、局部及新发复发率、无复发生存率、消融体积、时间及所需天线数量。对文献进行定性综述。

结果

本综述共纳入29项研究,报告了3250例患者和4500个肿瘤的数据。患者年龄中位数为60.5岁(范围3 - 91岁)。76.3%(2420例男性/753例女性)为男性。肝细胞癌(55%)是最常见的肿瘤病理类型,其次是结直肠癌肝转移(10%)和胆管癌(4%)。大多数研究报告了技术成功率(范围91.6 - 100%)、消融成功率(范围73.1 - 100%)以及主要并发症(范围0 - 9.1%)。21项研究报告了局部复发(范围0 - 50%);然而,新发复发(范围12.2 - 64%)报告较少(6项研究),其中12项、6项和4项研究进一步明确为肝内远处复发(11.3 - 54.2%)、肝外远处复发(3.6 - 20%)和转移(1.1 - 36%)。分别有3项、6项和5项研究报告了疾病进展率和无复发生存率。

结论

微波消融常用于肝恶性肿瘤的治疗。深入了解不同病理类型和MWA设备相关的临床结果,可提高外科医生的认知,并有助于手术规划和患者管理。为实现这一认知,需要文献中更一致地报告关键结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验